EnhancedBio

About EnhancedBio

EnhancedBio, a clinical-stage biopharmaceutical firm established in Seoul, South Korea in 2016, is focused on the development of novel anti-cancer therapeutics. The company directs its efforts towards creating first-in-class treatments for various cancers, with a particular specialization in diseases mediated by the Human Papilloma Virus (HPV).

The core of EnhancedBio's strategy involves a dual-platform approach, utilizing both small molecule drugs and advanced siRNA (small interfering RNA) therapies. Its product pipeline includes treatments aimed at inhibiting the viral oncogenes responsible for conditions such as cervical cancer. The company's business model is centered on advancing its proprietary drug candidates through the clinical trial phases to eventually secure regulatory approval and commercialize these treatments for cancer patients globally. This involves significant investment in research and development, preclinical studies, and multi-phase clinical trials.

A key asset in its portfolio is Borestrant (ZB716), an oral selective estrogen receptor degrader (SERD) being developed for patients with ER+/HER2- breast cancer. This lead compound has progressed to Phase 1/2 clinical trials. Another significant candidate is Cavisiran, an siRNA drug targeting HPV-mediated cancers. The company's technology also extends to a proprietary lipid nanoparticle (LNP) delivery system, crucial for its siRNA-based therapeutics. By developing treatments like Borestrant, which offers the convenience of oral administration over existing therapies, EnhancedBio aims to address limitations in the current standard of care for oncology patients.